Rein Therapeutics (NASDAQ:RNTX) Upgraded by Wall Street Zen to “Hold” Rating

Rein Therapeutics (NASDAQ:RNTX) was upgraded by equities research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued to investors on Saturday.

Separately, HC Wainwright lowered their price target on shares of Rein Therapeutics from $10.00 to $8.00 and set a “buy” rating on the stock in a report on Monday, June 1st. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $7.00.

Rein Therapeutics Stock Performance

NASDAQ:RNTX opened at $0.94 on Friday. Rein Therapeutics has a fifty-two week low of $0.94 and a fifty-two week high of $2.18. The stock has a market capitalization of $80.67 million, a P/E ratio of -0.50 and a beta of 1.35. The company’s 50-day simple moving average is $1.30 and its 200-day simple moving average is $1.29.

Rein Therapeutics (NASDAQ:RNTX) last released its quarterly earnings results on Friday, May 15th. The company reported ($0.19) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.30. On average, research analysts forecast that Rein Therapeutics will post -0.53 EPS for the current year.

Hedge Funds Weigh In On Rein Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Susquehanna International Group LLP purchased a new position in shares of Rein Therapeutics in the 3rd quarter valued at approximately $35,000. HRT Financial LP purchased a new position in shares of Rein Therapeutics in the 4th quarter valued at approximately $38,000. Chicago Partners Investment Group LLC raised its position in shares of Rein Therapeutics by 32.2% in the 1st quarter. Chicago Partners Investment Group LLC now owns 41,048 shares of the company’s stock valued at $53,000 after purchasing an additional 10,000 shares during the last quarter. Northwestern Mutual Wealth Management Co. purchased a new position in shares of Rein Therapeutics in the 2nd quarter valued at approximately $68,000. Finally, Jane Street Group LLC purchased a new position in shares of Rein Therapeutics in the 4th quarter valued at approximately $72,000. 90.89% of the stock is owned by hedge funds and other institutional investors.

About Rein Therapeutics

Rein Therapeutics is a clinical-stage biotechnology company focused on developing novel immuno-oncology therapies for patients with solid tumors. The company’s core technology is a tumor-activated interleukin-12 (IL-12) prodrug platform, designed to confine cytokine activity to the tumor microenvironment and thereby enhance anti-tumor immunity while minimizing systemic toxicity.

The lead candidate, RT-101, is currently in early-phase clinical trials targeting multiple solid tumor indications, including head and neck cancer and non-small cell lung cancer.